Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.

@article{Marinis2008ClinicalEF,
  title={Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.},
  author={F. De Marinis and Francesco Grossi},
  journal={The oncologist},
  year={2008},
  volume={13 Suppl 1},
  pages={14-20}
}
In the U.S. and Europe, the current options for the second- and third-line treatment of advanced non-small cell lung cancer (NSCLC) are cytotoxic drugs and targeted agents. Docetaxel was the first drug approved for second-line treatment after two phase III trials demonstrated its superiority over best supportive care (BSC) alone and single-agent chemotherapy. Pemetrexed was also registered for use as second-line therapy after it was demonstrated to have activity comparable with, and a more… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Erlotinib in lung cancer

  • FA Shepherd, L. Seymour
  • N Engl J Med
  • 2005

Similar Papers

Loading similar papers…